Atrial septal defect closure: indications and contra-indications von Fraisse, Alain, Latchman, Monica, Sharma, Shiv-Raj, Bayburt, Selin, Amedro, Pascal, di Salvo, Giovanni, Baruteau, Alban Elouen

Volltext

Abstract 4537: SBT6050, a HER2-directed TLR8 ImmunoTAC™therapeutic, is a potent human myeloid cell agonist that provides opportunity for single agent clinical activity von Comeau, Michael R., Brender, Ty, Childs, Monica, Brevik, Jamie, Winship, Damion, Metz, Heather, Chang, Jenny, Adamo, Jeffrey, Setter, Ben, Xu, Hengyu, Fan, Li-Qun, Stevens, Brenda, Smith, Sean W., Tan, Phil, DuBose, Robert, Latchman, Yvette, Baum, Peter, Odegard, Valerie

Volltext

SBT6050, a HER2-directed TLR8 therapeutic, as a systemically administered, tumor-targeted human myeloid cell agonist von Metz, Heather, Childs, Monica, Brevik, Jamie, Winship, Damion, Brender, Ty, Comeau, Michael, Moyes, Kara, Chang, Jenny, Adamo, Jeffrey, Setter, Ben, Xu, Hengyu, Fan, Li-Qun, Smith, Sean, Tan, Phil, DuBose, Robert, Latchman, Yvette, Baum, Peter, Odegard, Valerie

Volltext

Abstract PD4-09: Preclinical studies support the development of SBT6050, an anti-HER2 antibody conjugated to a potent TLR8 agonist, for treatment of moderate and high HER2-expressi... von Odegard, Valerie H, Moyes, Kara, Childs, Monica, Brevik, Jamie, Winship, Damion, Brender, Ty, Metz, Heather, Chang, Jenny R, Adamo, Jeffrey, Setter, Ben, Xu, Hengyu, Fan, Li-Qun, Smith, Sean W, Tan, Phil, DuBose, Robert, Latchman, Yvette, Baum, Peter

Volltext

Abstract 1858: SBT6290, a systemically administered Nectin4-directed TLR8 ImmunoTAC™ product candidate, is designed for tumor-localized activation of myeloid cells von Comeau, Michael R., Metz, Heather, Stevens, Brenda, Winship, Damion, Brevik, Jamie, Rhodehamel, Marcus, Childs, Monica, Hay, Elsa, Chang, Jenny, Fan, Li-Qun, Xu, Hengyu, Grey, Jonathan, Adamo, Jeffrey, Setter, Ben, Carillo, Ray, Smith, Sean W., Tan, Phil, Dubose, Robert, Latchman, Yvette, Baum, Peter, Odegard, Valerie

Volltext

712 SBT6290, a systemically administered Nectin-4-directed TLR8 ImmunoTAC (TM) therapeutic, is a potent human myeloid cell agonist for the treatment of Nectin-4-expressing tumors von Metz, Heather, Brender, Ty, Stevens, Brenda, Winship, Damion, Brevik, Jamie, Comeau, Michael, Childs, Monica, Chang, Jenny, Fan, Li-Qun, Xu, Hengyu, Grey, Jonathan, Adamo, Jeffrey, Setter, Ben, Carrillo, Ray, Smith, Sean, Tan, Phil, DuBose, Robert, Latchman, Yvette, Baum, Peter, Odegard, Valerie

Volltext

CREM: A Master-Switch in the Transcriptional Response to cAMP von Lamas, Monica, Monaco, Lucia, Zazopoulos, Emmanuel, Lalli, Enzo, Tamai, Katherine, Penna, Lucia, Mazzucchelli, Cristina, Nantel, Francois, Foulkes, Nicholas S., Sassone-Corsi, Paolo

Volltext